Inhibrx appoint Carlos Bais as Chief Scientific Officer

Inhibrx (INBX) Biosciences announced the departure of Brendan Eckelman, co-founder and Chief Scientific Officer, or CSO, and the appointments of Carlos Bais and David Matly to CSO and President, respectively. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and CEO. Inhibrx and the new company have entered into an exclusive license agreement for the rights to certain technologies no longer being pursued by Inhibrx. The agreement includes an upfront payment upon completion of the initial funding of Eckelman’s new company and other future development milestones. Additionally, the Company also announced the promotion of David Matly to President in addition to his existing roles as Chief Commercial and Business Development Officer. Bais began his career in the biopharmaceutical industry as a research lab head at Genentech and then as a Senior Director and Principal Scientist in the oncology biomarker development department. Later he served as a Director of Translational Medicine for cancer immunotherapy at Medimmune/Astrazeneca, and most recently prior to Inhibrx, as a Senior Director and Principal Scientist in the oncology biomarker development department at Genentech/Roche. Throughout his career, Dr. Bais led impactful research and translational strategies for multiple late-stage programs that resulted in high impact publications and drug approvals in diagnostic-positive patient subpopulations.